HOSE USD
Imexpharm Corporation (IMP.VN)
50,200.00
+700.00
+(1.41%)
At close: 2:45:10 PM GMT+7
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,308,077,163.31
2,205,119,938.41
1,994,036,910.38
1,643,706,514.65
1,266,596,707.35
Cost of Revenue
1,398,619,410.79
1,349,562,785.72
1,183,501,179.18
946,351,264.43
778,595,381.09
Gross Profit
909,457,752.53
855,557,152.69
810,535,731.20
697,355,250.22
488,001,326.26
Operating Expense
476,759,436.80
440,298,354.09
429,494,795.40
400,855,158.61
253,929,435.02
Operating Income
432,698,315.73
415,258,798.60
381,040,935.80
296,500,091.61
234,071,891.25
Net Non Operating Interest Income Expense
-16,881,826.45
-16,167,170.92
-12,238,267.65
-9,772,053.26
-8,574,810.90
Pretax Income
421,711,738.76
404,192,934.56
377,272,934.10
291,404,142.44
238,859,092.22
Tax Provision
88,308,461.51
83,330,541.47
77,716,928.56
67,863,824.84
49,764,217.26
Net Income Common Stockholders
309,164,858.99
297,535,697.11
277,778,283.94
183,843,543.12
173,513,335.40
Diluted NI Available to Com Stockholders
309,164,858.99
297,535,697.11
277,778,283.94
183,843,543.12
173,513,335.40
Basic EPS
2.01k
1.93k
1.80k
1.19k
1.13k
Diluted EPS
2.01k
1.93k
1.80k
1.19k
1.13k
Basic Average Shares
154,008.96
154,008.96
154,008.96
154,010.23
154,011.33
Diluted Average Shares
154,008.96
154,008.96
154,008.96
154,010.23
154,011.33
Total Operating Income as Reported
419,968,387.88
403,284,767.41
374,406,554.69
290,633,028.58
234,475,310.67
Total Expenses
1,875,378,847.59
1,789,861,139.82
1,612,995,974.57
1,347,206,423.04
1,032,524,816.10
Net Income from Continuing & Discontinued Operation
333,403,277.25
320,862,393.08
299,556,005.54
223,540,317.60
189,094,874.96
Normalized Income
331,297,541.34
319,482,210.22
299,556,005.54
223,566,887.14
188,252,043.37
Interest Income
10,067,753.27
7,884,086.61
16,885,258.19
13,861,337.09
7,886,669.37
Interest Expense
5,317,988.59
3,489,360.22
6,036,185.39
3,794,587.78
5,496,312.95
Net Interest Income
-16,881,826.45
-16,167,170.92
-12,238,267.65
-9,772,053.26
-8,574,810.90
EBIT
427,029,727.35
407,682,294.77
383,309,119.49
295,198,730.22
244,355,405.17
EBITDA
532,305,240.17
513,318,521.68
465,951,401.05
355,584,426.25
304,767,527.61
Reconciled Cost of Revenue
1,398,619,410.79
1,349,562,785.72
1,183,501,179.18
946,351,264.43
778,595,381.09
Reconciled Depreciation
105,275,512.81
105,636,226.91
82,642,281.57
60,385,696.03
60,412,122.44
Net Income from Continuing Operation Net Minority Interest
333,403,277.25
320,862,393.08
299,556,005.54
223,540,317.60
189,094,874.96
Total Unusual Items Excluding Goodwill
2,663,481.78
1,738,627.44
0
-34,635.69
1,064,640.12
Total Unusual Items
2,663,481.78
1,738,627.44
0
-34,635.69
1,064,640.12
Normalized EBITDA
529,641,758.39
511,579,894.24
465,951,401.05
355,619,061.95
303,702,887.49
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
557,745.86
358,444.58
0
-8,066.15
221,808.52
12/31/2021 - 4/2/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade